Our top pick for
Rubius Therapeutics, Inc is a biotechnology business based in the US. Rubius Therapeutics shares (RUBY) are listed on the NASDAQ and all prices are listed in US Dollars. Rubius Therapeutics employs 197 staff and has a market cap (total outstanding shares value) of USD$917.7 million.
|52-week range||USD$3.35 - USD$15.1|
|50-day moving average||USD$11.1862|
|200-day moving average||USD$6.9927|
|Wall St. target price||USD$11.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.696|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$0|
|Return on assets TTM||-28.9%|
|Return on equity TTM||-71.46%|
|Market capitalisation||USD$917.7 million|
TTM: trailing 12 months
There are currently 7.6 million Rubius Therapeutics shares held short by investors – that's known as Rubius Therapeutics's "short interest". This figure is 4.7% down from 8.0 million last month.
There are a few different ways that this level of interest in shorting Rubius Therapeutics shares can be evaluated.
Rubius Therapeutics's "short interest ratio" (SIR) is the quantity of Rubius Therapeutics shares currently shorted divided by the average quantity of Rubius Therapeutics shares traded daily (recently around 580962.16628528). Rubius Therapeutics's SIR currently stands at 13.11. In other words for every 100,000 Rubius Therapeutics shares traded daily on the market, roughly 13110 shares are currently held short.
However Rubius Therapeutics's short interest can also be evaluated against the total number of Rubius Therapeutics shares, or, against the total number of tradable Rubius Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Rubius Therapeutics's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Rubius Therapeutics shares in existence, roughly 90 shares are currently held short) or 0.2839% of the tradable shares (for every 100,000 tradable Rubius Therapeutics shares, roughly 284 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Rubius Therapeutics.
Find out more about how you can short Rubius Therapeutics stock.
We're not expecting Rubius Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Rubius Therapeutics's shares have ranged in value from as little as $3.35 up to $15.1. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Rubius Therapeutics's is 2.2235. This would suggest that Rubius Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.